- Home
- RNAC vs CAPR Comparison
RNAC vs CAPR Comparison
Compare RNAC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- CAPR
- Stock Information
- Founded
- RNAC 2007
- CAPR 2005
- Country
- RNAC United States
- CAPR United States
- Employees
- RNAC N/A
- CAPR N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNAC Health Care
- CAPR Health Care
- Exchange
- RNAC Nasdaq
- CAPR Nasdaq
- Market Cap
- RNAC 276.3M
- CAPR 324.6M
- IPO Year
- RNAC 2016
- CAPR N/A
- Fundamental
- Price
- RNAC $10.05
- CAPR $6.28
- Analyst Decision
- RNAC Strong Buy
- CAPR Strong Buy
- Analyst Count
- RNAC 4
- CAPR 8
- Target Price
- RNAC $40.00
- CAPR $24.75
- AVG Volume (30 Days)
- RNAC 48.4K
- CAPR 1.4M
- Earning Date
- RNAC 08-07-2025
- CAPR 08-11-2025
- Dividend Yield
- RNAC N/A
- CAPR N/A
- EPS Growth
- RNAC N/A
- CAPR N/A
- EPS
- RNAC N/A
- CAPR N/A
- Revenue
- RNAC $1,026,000.00
- CAPR $13,392,150.00
- Revenue This Year
- RNAC N/A
- CAPR N/A
- Revenue Next Year
- RNAC N/A
- CAPR $6,061.53
- P/E Ratio
- RNAC N/A
- CAPR N/A
- Revenue Growth
- RNAC N/A
- CAPR N/A
- 52 Week Low
- RNAC $8.46
- CAPR $3.98
- 52 Week High
- RNAC $26.50
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- RNAC 34.71
- CAPR 36.33
- Support Level
- RNAC $10.50
- CAPR $6.17
- Resistance Level
- RNAC $11.80
- CAPR $7.30
- Average True Range (ATR)
- RNAC 0.56
- CAPR 0.43
- MACD
- RNAC -0.11
- CAPR -0.11
- Stochastic Oscillator
- RNAC 0.45
- CAPR 4.53
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.